Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1969 Jan;48(1):23–32. doi: 10.1172/JCI105971

Studies on the prekallikrein (kallikreinogen)—kallikrein enzyme system of human plasma

II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein

Robert W Colman 1, Lawrence Mattler 1, Sol Sherry 1
PMCID: PMC322188  PMID: 4237065

Abstract

Evidence is presented in this paper that the kaolin-activated arginine esterase of plasma is related to plasma kallikrein activity. Such a relationship is based on studies that (1) establish a constant ratio of esterase activity on various synthetic substrates for the kaolin-activated arginine esterase, purified kallikrein(s), and preparations obtained during the fractionation procedure; (2) exclude other known plasma and tissue arginine esterases; (3) confirm the requirement for factor XII in the activation of the enzyme precursor; and (4) show similarities in behavior between the plasma esterase and purified kallikrein(s) toward a variety of inhibitors.

Based on this probable identification, evidence is provided that the concentration of active factor XII determines the rate of activation of plasma kallikreinogen, and that the activation may be blocked by polybrene. Once activated, plasma kallikrein is rapidly inactivated by the naturally occurring plasma inhibitor, but the inhibition is incomplete. Acid or chloroform treatment of plasma rapidly inactivates the plasma inhibitor without affecting the concentration of plasma kallikreinogen.

Another plasma arginine esterase with properties suggestive of permeability factor is activated by factor XII in the presence of synthetic substrates, but only at low ionic strength. The data suggest that this enzyme is closely related to plasma kallikrein and that it arises from a common precursor.

Full text

PDF
23

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cline M. J., Melmon K. L. Plasma kinins and cortisol: a possible explanation of the anti-inflammatory action of cortisol. Science. 1966 Sep 2;153(3740):1135–1138. doi: 10.1126/science.153.3740.1135. [DOI] [PubMed] [Google Scholar]
  2. Colman R. W., Mattler L., Sherry S. Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest. 1969 Jan;48(1):11–22. doi: 10.1172/JCI105959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Davies G. E., Holman G., Johnston T. P., Lowe J. S. Studies on kallikrein: failure of some anti-inflammatory drugs to affect release of kinin. Br J Pharmacol Chemother. 1966 Nov;28(2):212–217. doi: 10.1111/j.1476-5381.1966.tb01887.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. EISEN V. EFFECT OF HEXADIMETHRINE BROMIDE ON PLASMA KININ FORMATION, HYDROLYSIS OF P-TOSYL-L-ARGININE METHYL ESTER AND FIBRINOLYSIS. Br J Pharmacol Chemother. 1964 Feb;22:87–103. doi: 10.1111/j.1476-5381.1964.tb01546.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Erdös E. G. Hypotensive peptides: bradykinin, kallidin, and eledoisin. Adv Pharmacol. 1966;4:1–90. doi: 10.1016/s1054-3589(08)60097-6. [DOI] [PubMed] [Google Scholar]
  6. FORELL M. M. Therapy with kallikrein and protease inhibitors. Ann N Y Acad Sci. 1963 Feb 4;104:368–375. doi: 10.1111/j.1749-6632.1963.tb17679.x. [DOI] [PubMed] [Google Scholar]
  7. KAGEN L. J., LEDDY J. P., BECKER E. L. THE PRESENCE OF TWO PERMEABILITY GLOBULINS IN HUMAN SERUM. J Clin Invest. 1963 Aug;42:1353–1361. doi: 10.1172/JCI104819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. KAGEN L. J. SOME BIOCHEMICAL AND PHYSICAL PROPERTIES OF THE HUMAN PERMEABILITY GLOBULINS. Br J Exp Pathol. 1964 Dec;45:604–611. [PMC free article] [PubMed] [Google Scholar]
  9. KOCH W. Relationship between air temperature and mean radiant temperature in thermal comfort. Nature. 1962 Nov 10;196:587–587. doi: 10.1038/196587a0. [DOI] [PubMed] [Google Scholar]
  10. LANDERMAN N. S., WEBSTER M. E., BECKER E. L., RATCLIFFE H. E. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy. 1962 Jul-Aug;33:330–341. doi: 10.1016/0021-8707(62)90032-1. [DOI] [PubMed] [Google Scholar]
  11. MACKAY M. E., MILES A. A., SCHACHTER M., WILHELM D. L. Susceptibility of the guinea pig to pharmacological factors from its own serum. Nature. 1953 Oct 17;172(4381):714–716. doi: 10.1038/172714b0. [DOI] [PubMed] [Google Scholar]
  12. MARGOLIS J. The mode of action of Hageman factor in the release of plasma kinin. J Physiol. 1960 May;151:238–252. doi: 10.1113/jphysiol.1960.sp006434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. MCCONNELL D. J., KAGEN L. J., BECKER E. L. USE OF HEPARIN IN DISTINGUISHING PLASMA KALLIKREIN FROM PF/DIL. Proc Soc Exp Biol Med. 1965 Jul;119:652–656. doi: 10.3181/00379727-119-30262. [DOI] [PubMed] [Google Scholar]
  14. PENSKY J., LEVY L. R., LEPOW I. H. Partial purification of a serum inhibitor of C'1-esterase. J Biol Chem. 1961 Jun;236:1674–1679. [PubMed] [Google Scholar]
  15. RATNOFF O. D., MILES A. A. THE INDUCTION OF PERMEABILITY-INCREASING ACTIVITY IN HUMAN PLASMA BY ACTIVATED HAGEMAN FACTOR. Br J Exp Pathol. 1964 Jun;45:328–345. [PMC free article] [PubMed] [Google Scholar]
  16. SHERRY S., ALKJAERSIG N., FLETCHER A. P. ASSAY OF UROKINASE PREPARATIONS WITH THE SYNTHETIC SUBSTRATE ACETYL-L-LYSINE METHYL ESTER. J Lab Clin Med. 1964 Jul;64:145–153. [PubMed] [Google Scholar]
  17. SHERRY S., TROLL W. The action of thrombin on synthetic substrates. J Biol Chem. 1954 May;208(1):95–105. [PubMed] [Google Scholar]
  18. SIEGELMAN A. M., CARLSON A. S., ROBERTSON T. Investigation of serum trypsin and related substances. I. The quantitative demonstration of trypsinlike activity in human blood serum by a micromethod. Arch Biochem Biophys. 1962 Apr;97:159–163. doi: 10.1016/0003-9861(62)90058-9. [DOI] [PubMed] [Google Scholar]
  19. Sherry S., Alkjaersig N. K., Fletcher A. P. Observations on the spontaneous arginine and lysine esterase activity of human plasma, and their relation to Hageman factor. Thromb Diath Haemorrh Suppl. 1966;20:243–247. [PubMed] [Google Scholar]
  20. Sherry S., Alkjaersig N., Fletcher A. P. Comparative activity of thrombin on substituted arginine and lysine esters. Am J Physiol. 1965 Sep;209(3):577–583. doi: 10.1152/ajplegacy.1965.209.3.577. [DOI] [PubMed] [Google Scholar]
  21. TROLL W., SHERRY S. The activation of human plasminogen by streptokinase. J Biol Chem. 1955 Apr;213(2):881–891. [PubMed] [Google Scholar]
  22. TROLL W., SHERRY S., WACHMAN J. The action of plasmin on synthetic substrates. J Biol Chem. 1954 May;208(1):85–93. [PubMed] [Google Scholar]
  23. WEBSTER M. E., ATNOFF O. D. Role of Hageman factor in the activation of vasodilator activity in human plasma. Nature. 1961 Oct 14;192:180–181. doi: 10.1038/192180a0. [DOI] [PubMed] [Google Scholar]
  24. WEBSTER M. E., PIERCE J. V. Action of the kallikreins on synthetic ester substrates. Proc Soc Exp Biol Med. 1961 May;107:186–191. doi: 10.3181/00379727-107-26575. [DOI] [PubMed] [Google Scholar]
  25. Webster M. E., Innerfield I. Interrelationship of human plasma kallikrein and plasmin in inflammation. Enzymol Biol Clin (Basel) 1965;5(3):129–148. doi: 10.1159/000457987. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES